Astellas Pharma Inc.
and Daiichi Sankyo Co., Ltd.
are collaborating to form a compound library sharing partnership for approximately 400,000 selected compounds, in an effort to promote innovative R&D. The two companies will have access to the compound libraries that form the basis of their drug discovery research, and through High Throughput Screening (HTS), the companies can search for potentially beneficial compounds to develop new drugs. For a period of three years, both companies will be able to implement broad HTS using the shared compounds without restrictions on targeted disease areas. If one company identifies a candidate compound for development, the receiving company may develop and commercialize the new drug for any indication for human diseases.